Last reviewed 2026-04-20 · How we verify

MIRDAMETINIB

MIRDAMETINIB is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, providing a stable revenue stream. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Rash
• Diarrhea
• Nausea
• Musculoskeletal pain
• Vomiting
• Fatigue
• Alopecia
• Dry skin
• Cough
• Wheezing
• Peripheral swelling
• Dizziness

Serious adverse events

• COVID-19
• Nephrolithiasis
• Acute kidney injury
• Ischemic colitis
• Retinal vein occlusion
• Squamous cell carcinoma of skin
• Cerebrovascular accident
• Chronic obstructive pulmonary disease
• Left ventricular dysfunction
• Urinary tract infection

Key clinical trials

• Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (PHASE2)
• Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma (PHASE1, PHASE2)
• Individual Patient Compassionate Use of Mirdametinib
• MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (PHASE2)
• A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma (PHASE1, PHASE2)
• A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (PHASE2)
• Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK (PHASE1, PHASE2)
• SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.